Literature DB >> 9176713

Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level.

E Tobaruela1, J M Enriquez, M Diez, J Camunas, J Muguerza, J Granell.   

Abstract

The value of serial serum carcinoembryonic antigen (CEA) assay in the follow-up of colorectal cancer patients with metastatic lymph nodes and normal (< or = 5 ng/ml) preoperative CEA levels, was examined in this study. Thirty-eight patients were studied and compared with 22 patients with elevated CEA levels. The overall sensitivity of CEA for the diagnosis of recurrence was 36%. Postoperative CEA was strongly influenced by the site of recurrence. CEA monitoring showed the best results in patients who developed hepatic metastases (sensitivity 60%, specificity 94%, positive predictive value 60%, and negative predictive value 94%), and was ineffective for the detection of locoregional or pulmonary metastases. The results indicate that elevation of CEA in the postoperative course of these patients is an indicator of the presence of hepatic metastases. Postoperative CEA monitoring should not be omitted in Dukes C patients with normal preoperative levels, and is more reliable for the detection of liver metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176713     DOI: 10.1177/172460089701200104

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  4 in total

1.  Tumor angiogenesis predicts recurrence with normal serum carcinoembryonic antigen in advanced rectal carcinoma patients.

Authors:  H Ishikawa; H Fujii; K Yamamoto; T Morita; M Hata; F Koyama; S Terauchi; S Sugimori; T Kobayashi; H Enomoto; S Yoshikawa; T Nishikawa; H Nakano
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Metastatic colorectal cancer-past, progress and future.

Authors:  Kathryn Field; Lara Lipton
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

Review 3.  Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

Authors:  Jesús García-Foncillas; Eduardo Díaz-Rubio
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.340

Review 4.  Blood CEA levels for detecting recurrent colorectal cancer.

Authors:  Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.